MYNZ Stock Overview
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Mainz Biomed N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.87 |
52 Week High | US$6.00 |
52 Week Low | US$0.85 |
Beta | 0.24 |
1 Month Change | -15.63% |
3 Month Change | -18.02% |
1 Year Change | -74.59% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -91.30% |
Recent News & Updates
Shareholder Returns
MYNZ | US Biotechs | US Market | |
---|---|---|---|
7D | -8.9% | -2.5% | -3.2% |
1Y | -74.6% | -3.7% | 19.3% |
Return vs Industry: MYNZ underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: MYNZ underperformed the US Market which returned 19.3% over the past year.
Price Volatility
MYNZ volatility | |
---|---|
MYNZ Average Weekly Movement | 11.3% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MYNZ's share price has been volatile over the past 3 months.
Volatility Over Time: MYNZ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 68 | Guido Baechler | mainzbiomed.com |
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases.
Mainz Biomed N.V. Fundamentals Summary
MYNZ fundamental statistics | |
---|---|
Market cap | US$19.05m |
Earnings (TTM) | -US$26.30m |
Revenue (TTM) | US$895.48k |
21.2x
P/S Ratio-0.7x
P/E RatioIs MYNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MYNZ income statement (TTM) | |
---|---|
Revenue | US$895.48k |
Cost of Revenue | US$385.82k |
Gross Profit | US$509.66k |
Other Expenses | US$26.81m |
Earnings | -US$26.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.20 |
Gross Margin | 56.91% |
Net Profit Margin | -2,936.50% |
Debt/Equity Ratio | 183.6% |
How did MYNZ perform over the long term?
See historical performance and comparison